. Author manuscript; available in PMC: 2015 Mar 1.

Published in final edited form as: Clin Cancer Res. 2013 Dec 10;20(5):1087–1094. doi: 10.1158/1078-0432.CCR-13-2563

Table 3.

Efficacy of aspirin in secondary prevention of colorectal cancer

Efficacy of aspirin in secondary prevention of colorectal cancer
Name of Study group	Type	Study population (N)	Aspirin dose used	Result from aspirin use [Multivariate HR (95% CI)]
Aspirin/Folate Polyp Prevention Study(14)	Randomized controlled trial	1121 patients with H/O colorectal adenomas	81 mg or 325 mg/ day	In the 81 mg patient group: Unadjusted RR 0.81 (0.69–0.96) for developing any adenoma. Adjusted RR 0.83 (0.70–0.98) for developing any adenoma. In the 325 mg patient group: Unadjusted RR 0.96 (0.81–1.13) for developing any adenoma. Adjusted RR 0.95 (0.80–1.12) for developing any adenoma.
APACC Trial(57)	Randomized controlled trial	272 patients with H/O colorectal adenomas	300-mg or 160 mg/ day	In the 160 mg group: RR 0.85 (95% CI, 0.57–1.26) for recurrent adenoma In the 300 mg group: RR 0.61 (95% CI, 0.37–0.99) for recurrent adenoma
Colorectal Adenoma Prevention Study(13)	Randomized controlled trial	635 patients with H/O colorectal cancer	325 mg/ day	Adjusted RR 0.65 (95% CI, 0.46–0.91) for any recurrent adenoma

Abbreviations: CRC, colorectal cancer; HR, Hazard ratio; RR, relative risk.